Clinical Trial Update: Precision Medicine for Patients With Identified Actionable Mutations [Phase 2]

View source ↗

Summary

A Phase 2 precision medicine trial for patients with identified actionable mutations in solid tumors, lymphoma, and multiple myeloma was terminated, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Solid Tumor, Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2024-07-03